Introduction {#s1}
============

Cardiovascular diseases (CVDs) cause nearly one third of all deaths in human beings worldwide ([@B116]). Coronary atherosclerotic heart disease, also known as CHD, is the most common type of CVD and one of the deadly diseases among humans ([@B30]; [@B58]). The mortality rate of CHD is the highest among all CVDs, accounting for about 40% of all CVD-related deaths ([@B88]; [@B153]). Numerous studies have shown that diabetes, hypertension, dyslipidemias, abdominal obesity, unhealthy diet, smoking, and psychosocial stress are major risk factors for CHD ([@B18]; [@B34]; [@B1]). CHD events were defined as hospitalization for unstable angina pectoris (UAP), myocardial infarction (MI), percutaneous coronary intervention (PCI) or coronary artery bypass grafting, and cardiovascular death ([@B69]). A number of multicenter randomized clinical trials have been conducted and provided more evidence for the treatment of CVDs by traditional Chinese medicine (TCM) ([@B11]; [@B64]; [@B54]; [@B134]).

*Salvia miltiorrhiza* Bunge (SM), known as Danshen, belongs to the family *Labiatae* and is widely used in TCM as a traditional natural medicine in clinics for several decades in various parts of China ([@B151]; [@B7]). Danshen has curative effect alone or in combination with other TCM groups. SM is used to treat malignant tumors, neurological, metabolic disorders, lung diseases, CVDs, inflammatory diseases, gynecological diseases, liver diseases, and renal diseases ([@B6]; [@B14]; [@B132]; [@B84]). The chemical constituents from the root extract of SM are divided into two categories: liposoluble tanshinones and water-soluble phenolics ([@B21]; [@B42]; [@B98]), most of which have been identified and purified using various chromatographic and spectroscopic methods ([@B150]). SM contains more than 40 lipophilic constituents and 50 hydrophilic constituents ([@B148]; [@B23]); which are mainly extracted as tanshinone I, tanshinone IIA (TsIIA), tanshinone IIB, cryptotanshinone, and dihydrotanshinone I ([**Figure 1**](#f1){ref-type="fig"}) ([@B67]). The major phenolic acid constituents among salvianolic acids are salvianolic acid A (Sal A), salvianolic acid B (Sal B), lithospermic acid, danshensu, caffeic acid, and rosmarinic acid ([**Figure 2**](#f2){ref-type="fig"}) ([@B39]; [@B66]; [@B92]). Salvianolates are the main water-soluble bioactive compounds extracted from SM and are composed of Sal B, rosmarinic acid, and lithospermic acid, which are widely used in the treatment of CHD ([@B82]; [@B85]). Tanshinones from SM are more effective against treatment of CVDs and cerebrovascular diseases, including atherosclerosis (AS), MI, cardiac hypertrophy ([@B31]), myocardial ischemia reperfusion (I/R) ([@B53]), and chronic heart failure (HF) ([@B38]). The most studied class of tanshinones is TsIIA, which is one of the major bioactive components of SM having less water solubility compared with other tanshinones ([@B152]). Sodium TsIIA sulfonate (STS) ([**Figure 3**](#f3){ref-type="fig"}) is a water-soluble derivative of TsIIA, which has been widely used in China for the treatment of CVDs safely and effectively, including MI and angina pectoris (AP) ([@B141]; [@B70]; [@B152]). Previous studies provided information on SM and its bioactive constituents for their various pharmacological activities, so in this review, we outlined the cardiovascular protective effects of TsIIA and STS, providing details about therapeutic mechanisms of CVDs, as well as the application of SM in clinical CVDs.

![Chemical structures of major tanshinones.](fphar-10-00753-g001){#f1}

![Chemical structures of major salvianolic acids.](fphar-10-00753-g002){#f2}

![Chemical structures of sodium tanshinone IIA sulfonate.](fphar-10-00753-g003){#f3}

Methods {#s2}
=======

The Gene Cloud of Biotechnology Information (GCBI) and PubMed databases were used to search for antioxidative, anti-inflammatory, endothelial protective, ischemia/reperfusion, myocardial, anticoagulation, vasodilating, smooth muscle cell, anti-AS, and tanshinones, respectively. The literature data related to the pharmacological effects of TsIIA and STS were manually screened out. Furthermore, the GCBI and PubMed databases were used to search for Danshen, *Salvia miltiorrhiza*, tanshinones, TsIIA, sodium TsIIA sulfonate, salvianolate, and CVDs, respectively.

The Pharmacological Effects of TsIIA, Sodium TsIIA Sulfonate, and Salvianolate {#s3}
==============================================================================

Recent research has demonstrated that TsIIA or STS or salvianolate has numerous cardioprotective effects, including antioxidative ([@B25]; [@B125]), inhibition of apoptosis ([@B15]; [@B137]), anti-inflammatory ([@B72]; [@B26]), anti-cardiac fibrosis ([@B117]), anti-cardiac hypertrophy ([@B27]), anticoagulation ([@B68]), anti-AS ([@B61]; [@B72]), and vasodilating ([@B56]); also reduction of macrophage derived foam cell formation ([@B61]), inhibition of proliferation, and migration of vascular smooth muscle cells (VSMCs) ([@B109]; [@B23]) ([**Figure 4**](#f4){ref-type="fig"}). Therefore, TsIIA and STS can be used as a promising candidate for treating CVDs ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}).

![Cardiovascular pharmacological effects of TsIIA, STS, and salvianolate (modified based on Li et al., 2018).](fphar-10-00753-g004){#f4}

###### 

*In vitro* cardiovascular effects of TsIIA, STS and Salvianolate.

  Effects                                          TsIIA/STS      Cell system                    Targets                                                          References
  ------------------------------------------------ -------------- ------------------------------ ---------------------------------------------------------------- ------------------
  Anti-oxidative                                   TsIIA          H9c2                           Nrf2                                                             ([@B33])
  Anti-oxidative                                   STS            H9c2                           Cell cycle arrest, oxidative stress, apoptosis                   ([@B146])
  Endothelial protective                           TsIIA          HUVECs                         Multiple ways of post-transcriptional mechanism                  ([@B56])
  Endothelial protective                           STS            HUVECs                         PI3K/AKT/eNOS pathway                                            ([@B17])
  Endothelial protective                           Salvianolate   Primary cardiomyocyte          Smad2/3, TGFβ1                                                   ([@B25])
  Protective effect against I/R                    TsIIA          Myocardial cell                PI3K/Akt/mTOR signaling Pathway                                  ([@B53])
  Myocardial protective                            TsIIA          MMEC                           Apoptosis, JAK2/STAT3 signaling pathway                          ([@B20])
  Myocardial protective                            Salvianolate   H9c2                           Apoptosis, ATP level                                             ([@B137])
  Anti-cardiac hypertrophy                         TsIIA          H9c2                           IGF-2R pathway                                                   ([@B16])
  Anti-cardiac fibrosis                            STS            Human atrial fibroblasts       Oxidative stress, TGF-β1 signaling pathway                       ([@B13])
  Anti-cardiac remodeling                          TsIIA          H9c2                           β-catenin and IGF-2R pathways, apoptosis                         ([@B15])
  Anti-cardiac remodeling                          TsIIA          Human cardiac fibroblasts      ECM remodeling responses                                         ([@B71])
  Vasodilating                                     TsIIA          HUVECs                         eNOS, multiple ways of post-transcriptional mechanism            ([@B56])
  Reduction of VSMCs migration and proliferation   TsIIA          Primary VSMCs                  ERK1/2 MAPK signaling pathway                                    ([@B62])
  Reduction of VSMCs migration and proliferation   STS            Primary VSMCs                  AMPK-p53-p21 signaling, AMPK/NF-κB signaling                     ([@B120])
  Anti-atherosclerosis                             STS            HUVECs                         Anti-oxidant, anti-inflammation, CLIC1                           ([@B152])
  Anti-atherosclerosis                             TsIIA          EPCs                           TNF-α, anti-inflammation                                         ([@B113])
  Anti-atherosclerosis                             TsIIA          Primary VSMCs, RAW264.7        Apoptosis, anti-inflammation                                     ([@B107])
  Anti-atherosclerosis                             TsIIA          Human monocyte-derived THP-1   ABCA1/ABCG1, ERK/Nrf2/HO-1                                       ([@B61])
  Anti-atherosclerosis                             TsIIA          HUVECs, EPCs                   TNF-α, VCAM-1, ICAM-1, IKK/NF-κB signaling pathway               ([@B9]; [@B127])
  Anti-atherosclerosis                             TsIIA          Human monocyte-derived DCs     Pro-inflammatory cytokines, atherosclerotic plaque instability   ([@B51])

###### 

*In vivo* cardiovascular effects of TsIIA, STS, and Salvianolate.

  Effects                                          TsIIA/STS      Animals   Targets                                                                                     References
  ------------------------------------------------ -------------- --------- ------------------------------------------------------------------------------------------- ------------
  Anti-oxidative                                   TsIIA          Mice      Nrf2                                                                                        ([@B33])
  Anti-oxidative                                   STS            Rat       NF-κB pathway                                                                               ([@B83])
  Anti-inflammatory                                Salvianolate   Rat       IL-6, CRP                                                                                   ([@B72])
  Endothelial protective                           TsIIA          Rat       ET-1, ET~B~ receptors, ET~A~ receptors, eNOS, NO                                            ([@B12])
  Protective effect against I/R                    TsIIA          Rat       PI3K/Akt pathway, mPTP                                                                      ([@B135])
  Protective effect against I/R                    TsIIA          Rat       PI3K/Akt/mTOR signaling pathway                                                             ([@B53])
  Protective effect against I/R                    TsIIA          Rat       ROS, HMGB1, anti-inflammatory                                                               ([@B40])
  Protective effect against I/R                    STS            Rat       Anti-inflammatory, apoptosis, autophagy                                                     ([@B78])
  Protective effect against I/R                    STS            Rat       Myocardial zymogram, anti-oxidant, HO-1                                                     ([@B114])
  Protective effect against I/R                    Salvianolate   Mice      ERK1/2                                                                                      ([@B82])
  Protective effect against I/R                    TSI            Rat       NDUFA10, SDHA, Sirt1, Sirt3                                                                 ([@B41])
  Anti-cardiac hypertrophy                         TsIIA          Rat       Cys-C/Wnt signaling pathway                                                                 ([@B27])
  Anti-cardiac fibrosis                            TsIIA          Rat       TLR4/MyD88/NF-κB signaling pathway                                                          ([@B117])
  Anti-cardiac remodeling                          TsIIA          Rat       SIRT1 signaling pathway, anti-oxidant, anti-inflammatory                                    ([@B26])
  Anticoagulation                                  TsIIA          Rabbit    TNF-α, hemostatic parameters, liver and renal injuries                                      ([@B118])
  Anticoagulation                                  TsIIA          Mice      ERK2 phosphorylation, blood viscosity, microcirculation                                     ([@B68])
  Vasodilating                                     TsIIA          Rat       eNOS, multiple ways of post-transcriptional mechanism                                       ([@B56])
  Vasodilating                                     STS            Rat       BK~Ca~ channel, Ca^2+^ channel                                                              ([@B147])
  Reduction of VSMCs migration and proliferation   STS            Rat       In a dose-dependent manner                                                                  ([@B109])
  Anti-atherosclerosis                             TsIIA          Rat       Lipid deposition, the distribution of HDL subfractions, intake, and efflux of cholesterol   ([@B46])
  Anti-atherosclerosis                             TsIIA          Mice      Porphyromonas gingivalis, anti-inflammatory                                                 ([@B125])
  Anti-atherosclerosis                             TsIIA          Mice      Anti-inflammatory, atherosclerotic plaque instability                                       ([@B149])
  Anti-atherosclerosis                             STS            Mice      Anti-oxidant, anti-inflammation, CLIC1                                                      ([@B152])
  Anti-atherosclerosis                             Salvianolate   Rat       IL-6, CRP, regulatory T cell                                                                ([@B72])

Antioxidative Effect {#s3_1}
--------------------

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a central regulator of cellular responses to oxidative stress, which plays a critical role in maintaining normal cardiac function ([@B33]). Nrf2-dependent antioxidant response mediates the protective effect of TsIIA on doxorubicin (DOX)-induced cardiotoxicity, suggesting that TsIIA may be a promising therapeutic adjuvant that prevents the serious side effects of DOX in the heart ([@B33]). Differentiation of atrial fibroblasts into myofibroblasts plays a pivotal role in atrial fibrosis ([@B13]). Studies have shown that STS prevents (angiotensin II) Ang II-induced myofibroblast differentiation through inhibiting oxidative stress and suppressing transforming growth factor-β1 (TGF-β1) signaling pathway in human atrial fibroblasts ([@B13]). STS may also protect cells from X-ray-induced cell cycle arrest, oxidative stress, and apoptosis during the treatment of radiation-induced cardiovascular damage ([@B146]). In addition, STS acts as an antioxidant for inhibiting hemorrhagic shock (HS)-induced organ failure by inhibiting the nuclear factor kappa B (NF-κB) pathway ([@B83]). Excessive amounts of reactive oxygen species (ROS) cause irreversible damage to DNA, cell membranes, and other cellular structures by oxidizing proteins, lipids, and nucleic acids ([@B24]; [@B152]). Salvianolate may inhibit the production of ROS and increase the antioxidant capacity of cardiomyocytes ([@B25]). Salvianolate also improved microvascular reflow by inhibiting oxidative stress and apoptosis ([@B35]).

Anti-Inflammatory Effect {#s3_2}
------------------------

AS is a chronic inflammatory disease of the arterial wall, which is characterized by progressive lipid accumulation in the aortic intima leading to endothelial cell dysfunction and further destruction of the endothelial barrier and vascular tone ([@B80]). Its pathogenesis is maladaptive immune response and cholesterol metabolism disorder ([@B89]; [@B8]). Inflammation is dominant in AS and CVDs ([@B104]). Recent studies showed that TsIIA and its derivatives are able to treat CVDs by decreasing the associated inflammatory responses. TsIIA significantly alleviated transverse aortic constriction (TAC)-induced myocardial remodeling by activating the silent information regulator 1 (SIRT1) signaling pathway, probably because it exerts strong antioxidant and anti-inflammatory activities ([@B26]). STS reduced the expression of tumor necrosis factor-α (TNF-α), interleukin (IL)-6, chloride intracellular channel 1 (CLIC1), vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) in the atherosclerotic mice; also the antioxidant and anti-inflammatory properties are mediated by inhibiting the expression of CLIC1 and membrane translocation ([@B152]). Salvianolate can reduce serum IL-6 and C-reactive protein (CRP) levels in AS rats in a dose-dependent manner ([@B72]). In addition, the level of IL-6 in macrophages after salvianolate treatment was also significantly reduced ([@B97]).

Endothelial Protective Effect {#s3_3}
-----------------------------

Endothelial nitric oxide synthase (eNOS) is the key enzyme that plays an important role in maintaining the homeostasis of vascular endothelial cells ([@B56]), as the endothelial cell dysfunction is the basis for the development of various cardiovascular complications of diabetes ([@B32]). Also, the TsIIA inhibited the decrease of eNOS expression and the generation of nitric oxide (NO) induced by high glucose, which exerted this effect through a variety of post-transcriptional mechanisms ([@B56]). TsIIA plays a protective role by inhibiting strain-induced endothelin-1 (ET-1) expression, increasing the endothelin type B (ET~B~) receptors, reducing the ET~A~ receptors, upregulating eNOS, and increasing the formation of NO during chronic intermittent hypoxia (CIH)-induced endothelial dysfunction ([@B12]). Furthermore, STS has multiple functions in vascular endothelial cells; it inhibits the apoptosis of human umbilical vein endothelial cells (HUVECs) induced by heat stress through phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/eNOS signaling pathway ([@B17]). Oxygen-free radicals impair NO-mediated coronary vasorelaxation affecting basal and agonist-induced NO release and may lead to endothelial dysfunction ([@B81]). Salvianolate inhibited ROS production by downregulating of transcription factors Smad2 and Smad3 (Smad2/3) and TGF-β1 expression, but high concentrations of salvianolate caused cytotoxicity in mouse cardiomyocytes ([@B25]). Sal A and Sal B protect HUVECs ([@B128]) and human aortic endothelial cells (HAECs) ([@B130]) from damage and improve blood--brain barrier dysfunction ([@B129]) by attenuating the production of ROS.

Protective Effect Against Ischemia/Reperfusion {#s3_4}
----------------------------------------------

I/R injury is considered to be the main cause of CHD, which is characterized by aggravation of functional damage, accelerated myocardial cell death, and arrhythmia ([@B47]; [@B133]). Studies have demonstrated that the PI3K/Akt pathway is involved in the cardioprotective effects provided by pharmacological pre- and post-conditioning by inhibiting mitochondrial permeability transition pore (mPTP) opening ([@B105]; [@B5]; [@B135]). Compared with the I/R model group, the group treated with TsIIA (10 mg/kg, IV) prior to reperfusion decreased myocardial infarct size, elevated levels of phosphor-Akt and phosphor-eNOS, and attenuated mitochondrial permeability transition ([@B135]). Therefore, pharmacological post conditioning with TsIIA can protect the myocardium from I/R injury by activating PI3K/AKT-eNOS pathway, and the blockage of mPTP opening may be involved in the cardioprotective effect ([@B135]). TsIIA also activated the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway to attenuate myocardial I/R injury in rats ([@B53]). Furthermore, TsIIA may inhibit the increased ROS formation caused by myocardial I/R, reduce the expression of the high mobility group box B1 protein (HMGB1), and inhibit inflammation reaction in the myocardial tissue ([@B40]). Moreover, STS improved I/R-induced myocardial damage by reducing inflammation and apoptosis, enhancing autophagy ([@B78]). Changes in serum myocardial zymograms (such as creatine kinase-MB, aspartate transaminase, lactate dehydrogenase) can be used as indicators to determine the alterations of membrane integrity and degree of myocardial injury ([@B79]; [@B114]). STS reduced some consequences of myocardial ischemia, including cardiac antioxidant status, serum myocardial zymogram, microstructural disorders, and cardiac function ([@B114]). The optimal treatment time window for STS treatment of myocardial I/R injury appears to be within 2 h after reperfusion ([@B114]). Salvianolate can reduce myocardial I/R injury in rats by reducing mitochondrial DNA oxidative damage, protecting mitochondrial function, and inhibiting cardiomyocyte apoptosis ([@B136]). It also can reduce myocardial I/R injury in mice, which involves the extracellular signal-regulated kinase (ERK)1/2 signaling pathway but not the PI3K signaling pathway ([@B82]). In addition, total salvianolic acid injection (TSI) attenuated I/R-induced myocardial damage by inhibiting oxidative stress, which is related to the activation of Nicotinamide adenine dinucleotide dehydrogenase \[ubiquinone\] 1 alpha subcomplex 10 (NDUFA10) and succinate dehydrogenase complex, subunit A, and flavoprotein variant (SDHA) by upregulating Sirtuin1 (Sirt1) and Sirtuin3 (Sirt3) ([@B41]).

The Myocardial Protective Effect {#s3_5}
--------------------------------

When myocardial cells undergo pathological injury, such as hypoxia injury, I/R injury, cardiac surgery, and diabetic injury, the pathological process can evolve from initial cell edema to degeneration and necrosis of myocardial hypertrophy and fibrosis ([@B30]). Under the condition of hypoxia/reoxygenation (H/R) injury in rats, TsIIA may alleviate myocardial microvascular endothelial cell (MMEC) apoptosis through inhibiting the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway and regulating the expressions of tumor suppressor p53, B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), and caspase-3 ([@B20]). Salvianolate may reduce oxidative damage of mitochondrial DNA, protect mitochondrial function, and inhibit cardiomyocyte apoptosis, thereby reducing H/R injury of cardiomyocytes ([@B137]). In case of cardiac hypertrophy in spontaneously hypertensive rats (SHRs), it was demonstrated that TsIIA may inhibit cardiac hypertrophy by inhibiting the cystatin c (Cys-C)/Wingless (Wnt) signaling pathway ([@B27]). TsIIA also attenuates the Ang II-induced pathological hypertrophy by estrogen receptors (ERs) in H9c2 cardiomyoblast cells ([@B16]). Furthermore, it was reported that TsIIA attenuated MI and cardiac fibrosis in rats by inhibiting Toll-like receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/NF-κB signaling pathway ([@B117]). Sal B can alleviate myocardial fibrosis by reducing Ang II-induced NF-κB activation *in vitro*, thus reversing the process of myocardial fibrosis ([@B108]).

Ventricular compensation and secondary pathophysiological responses are accompanied by a series of ventricular myocardial damage and ventricular remodeling for the pathological repair ([@B30]). A study proved that TsIIA attenuated β-catenin and insulin-like growth factor-II receptor (IGF-2R) pathways, decreased subsequent apoptosis and cardiac remodeling, and promoted survival in H9c2 cardiomyoblasts ([@B15]). There is evidence that TsIIA significantly ameliorated myocardial remodeling induced by pressure overload through SIRT1 signaling pathway in TAC rats ([@B26]). TsIIA is important for the treatment of pathological cardiac remodeling; it can inhibit Ang II-induced extracellular matrix (ECM) remodeling responses in human cardiac fibroblasts ([@B71]).

Anticoagulation Effect {#s3_6}
----------------------

Under physiological conditions, coagulation and hemostasis system in the human body are mutually restricted by anticoagulation and fibrinolytic system, but they are in a state of dynamic balance. In pathological conditions, no matter which system is abnormal, it can cause bleeding or thrombosis. There is evidence that TsIIA exerts a significant protective effect against lipopolysaccharide (LPS)-induced disseminated intravascular coagulation (DIC) in rabbits. TsIIA also can improve organ injury and reduce the lethal effects of LPS-treated animals ([@B118]). TsIIA inhibits platelet aggregation induced by adenosine diphosphate (ADP) and collagen via regulating the acetylation of tubulin and inhibiting ERK2 phosphorylation. Therefore, the compound from SM is a promising drug that can improve blood viscosity and microcirculation to prevent CVDs ([@B68]).

Vasorelaxant Effect {#s3_7}
-------------------

The vasculature plays a vital role in maintaining blood pressure and providing adequate hemoperfusion based on dynamic physical conditions ([@B30]). Impaired endothelium-dependent vasodilation has been thought to play a major role in the development of cardiovascular complications of diabetes ([@B56]). It was demonstrated that TsIIA may improve impaired endothelium-dependent vasodilation induced by diabetes via enhancing eNOS expression and activity ([@B56]), and this effect was initiated by a variety of mechanisms at the post-transcriptional level of eNOS, including regulation of eNOS mRNA and protein stability, coupling, and serine 1177 phosphorylation ([@B56]). Furthermore, STS also exerts vasodilation effect, which not only activated large conductance Ca^2+^-activated K^+^ (BK~Ca~) channel but also blocked Ca^2+^ channel and inhibited Ca^2+^ influx in the VSMCs of rats ([@B147]). Danshen water-soluble extract and Sal B exert their vasorelaxant effects by inhibiting Ca^2+^ influx in VSMCs, and the opening of K^+^ channels has minor contribution to their effects, but does not involve endothelium-dependent mechanism ([@B50]). The vasodilatation of Sal B depends, at least in part, on NO and its vasodilation associated NO-guanylate cyclase (GC)-cyclic guanosine 3′,5′-monophosphate (cGMP) signals ([@B94]).

Reduction of Smooth Muscle Cell Migration and Proliferation {#s3_8}
-----------------------------------------------------------

VSMCs play a major role in the pathogenesis of diabetic vascular disease; TsIIA treatment significantly attenuated advanced glycation end products (AGEs)-induced proliferation and migration of VSMCs by inhibiting ERK1/2 mitogen-activated protein kinase (MAPK) signaling pathway ([@B62]). Therefore, TsIIA may be a potential candidate for the prevention of diabetic AS ([@B62]). Furthermore, STS may inhibit high glucose-induced VSMCs proliferation and migration via AMP-activated protein kinase (AMPK) activation; it exerts anti-proliferative effect through activating the AMPK-p53-p21 signaling pathway and anti-migration effect by inhibiting AMPK/NF-κB ([@B120]). These facts prove that STS can be used to prevent AS and restenosis after PCI ([@B120]), and it helps to prevent the development of pulmonary arterial hypertension (PAH) by inhibiting the expression of canonical transient receptor potential (TRPC)1 and TRPC6, leading to normalized basal intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) and attenuated the proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) ([@B109]). Sal B, a major component of salvianolate, inhibited stromal cell-derived factor-1α (SDF-1α)-stimulated cell proliferation and VSMCs migration by inhibiting C-X-C chemokine receptor type 4 (CXCR4) receptor ([@B77]).

Anti-AS Effect {#s3_9}
--------------

AS is an inflammatory disease that causes hardening and thickening of the arterial wall and the formation of plaques, including mesenchymal cells, immune cells, lipids, and ECM ([@B96]). Lesions mainly occur in large and medium elastic muscle arteries, which may cause ischemia of the brain, heart, and extremities, or stroke ([@B29]). The lesions may exist throughout the entire life of the person through circulation of oxidized low-density lipoprotein (ox-LDL) and other pro-atherosclerotic risk factors (such as hyperhomocysteinemia, hyperglycemia) that trigger multiple major pro-atherogenic events, such as endothelial dysfunction, proliferation, and migration of VSMCs, macrophage-derived foam cell formation, T lymphocyte infiltration, and thrombosis ([@B29]; [@B124]; [@B123]; [@B99]; [@B23]).

TsIIA can affect high-density lipoprotein (HDL) subtractions distribution and the intake and efflux of cholesterol ([@B46]); inhibit endothelial progenitor cell (EPC) injury ([@B113]), apoptosis of VSMCs ([@B107]), proliferation and migration of macrophages ([@B107]), foam cell formation ([@B61]), and vascular inflammation ([@B127]; [@B107]; [@B125]); and enhance vulnerable plaque stability ([@B55]; [@B149]). These effects can inhibit the progression of AS. TNF-α impaired EPCs' proliferation, migration, adhesion, and vasculogenesis ability *in vitro* and promoted EPC secretion of inflammatory cytokines, including IL-6, soluble form of CD40 ligand (sCD40L), and monocyte chemoattractant protein 1 (MCP-1), but TsIIA can reverse these effects ([@B113]). TsIIA attenuated ox-LDL-induced apoptosis of VSMCs, inhibited ox-LDL-induced proliferation and migration of RAW264.7 cells, and inhibited upregulation of TNF-α, IL-1β, IL-6, and MCP-1 in RAW264.7 cells treated with ox-LDL ([@B107]); TsIIA reduced scavenger receptor class A (SR-A)-mediated ox-LDL uptake by inhibiting activator protein-1 and increased ATP-binding cassette transporter A1 (ABCA1)/ABCG1-mediated cholesterol efflux through the ERK/Nrf2/heme oxygenase-1 (HO-1) pathway, ultimately leading to reduced cholesterol accumulation in foam cells and atherosclerotic plaques ([@B61]). In HUVECs ([@B9]) and EPCs ([@B127]), the TNF-α-induced VCAM-1 and ICAM-1 expression is regulated by inhibiting TNF-α-induced nuclear translocation of NF-κB and activation of IκB kinases (IKK)/NF-κB signaling pathway. TsIIA can also prevent inflammatory responses induced by *Porphyromonas gingivalis* infection in apolipoprotein E knockout mice (ApoE^-/-^) mice, and reduce the expression of inflammatory mediators associated with progression of AS ([@B125]). These demonstrated the anti-inflammatory effect of TsIIA in AS. Furthermore, the anti-inflammatory and antioxidant properties of STS in the prevention of AS are mediated by inhibition of CLIC1 expression and membrane translocation ([@B152]). TsIIA inhibited dendritic cell (DC) maturation and reduced the expression of pro-inflammatory cytokines while attenuating their ability to stimulate T-cell proliferation and cytokine secretion, which may contribute to the pathophysiological processes involved in atherosclerotic plaque instability ([@B51]). The potential mechanism by which TsIIA stabilized vulnerable plaques in ApoE^-/-^ mice may interfere with AGEs and NF-κB activation, as well as downregulation of downstream inflammatory factors, including ICAM-1, VCAM-1, and matrix-metalloproteinases (MMP)-2, -3, and -9 ([@B149]). Salvianolate treatment can dose-dependently reduce AS by reducing the levels of pro-inflammatory cytokines and increasing the number of regulatory T cells ([@B72]).

*S. miltiorrhiza* for the Treatment of Clinical Cardiovascular Diseases {#s4}
=======================================================================

TsIIA is currently used in China for the treatment of patients with CHD and ischemic stroke, but TsIIA is not easily absorbed by the intestinal pathway, and then STS injection has been developed to improve the bioavailability of the herbal medicine ([@B134]). Danshen, Danhong, salvianolate, STS injections, and other SM preparations are widely used in China to treat stable AP (SAP) caused by CHD ([@B139]). Salvianolate injections are composed of water-soluble extract of SM ([@B35]; [@B52]). Danhong injection is a modern patented Chinese medicine extracted from SM and *Flos Carthami* ([@B154]; [@B28]). It was approved by the China Food and Drug Administration (FDA) in 2002 ([@B154]). Compound Danshen dripping pills (CDDP) are a modern Chinese medicine preparation consisting of SM, *Panax notoginseng*, and borneol ([@B45]). It is the first TCM approved by the American FDA for the treatment of CVDs in Phase II clinical trials ([@B65]; [@B144]). Therefore, the clinical preparations of SM are mainly divided into three categories: simple monomer preparation, such as STS injection; water-soluble complex, such as salvianolate and Danshen injection; and compound preparation of SM, such as CDDP; also the form of SM preparation includes tablets, injections, capsules, formulations, and drop pills ([@B59]). This article summarizes the scientific literature that reported the effects of SM on clinical CVDs like CHD, hyperlipidemia, and hypertension ([**Table 3**](#T3){ref-type="table"}).

###### 

Clinical trials of *S. miltiorrhiza* preparations for controlling cardiovascular diseases.

  Diseases                          Preparations                                 Dose                                    Duration                 Cases/controls   Primary outcome measures                                                   References
  --------------------------------- -------------------------------------------- --------------------------------------- ------------------------ ---------------- -------------------------------------------------------------------------- ------------
  SAP                               Salvianolate injection, Danshen drop pills   200 mg/qd, 30 pills/qd                  10 days, 60 days         78/78            SAQ, frequency of AP, angina grade, consumption of short-acting nitrates   ([@B10])
  UAP                               STS injection                                60 mg/qd                                4 weeks                  46/48            FIB level, DD levels, frequency of AP                                      ([@B126])
  NSTEMI                            SM                                           3 g/qd, 1 g each time                   One month                26/26            ADMA level                                                                 ([@B140])
  Hypertension                      Fufang Danshen capsule                       1 g, twice-daily                        12 weeks                 30/25            Systolic blood pressure, pulse rate                                        ([@B131])
  PH                                STS                                          1 g/kg/day                              8 weeks                  5/-              Exercise capacity, Borg dyspnea score                                      ([@B110])
  Congenital heart defects and PH   SM                                           200 mg/kg                               Before cardiac surgery   10/10            ET-1 response, hemodynamic stability                                       ([@B121])
  Hyperlipidemia                    CDDP                                         30 capsules/qd, 10 capsules each time   3 months                 38/37            Blood lipid levels                                                         ([@B145])

SAP and UAP {#s4_1}
-----------

AP can be divided into SAP and UAP. UAP is a common coronary syndrome between SAP and acute MI, which can easily lead to MI or sudden death ([@B102]). Chronic SAP accounts for about 50% of all patients with coronary artery disease (CAD) ([@B10]). Symptoms of chronic SAP are highly associated with the development of atherosclerotic plaque, which blocks at least one large epicardial coronary artery and triggers an imbalance between myocardial oxygen supply and demand ([@B10]).

In a randomized, single-blinded, placebo-controlled, adaptive clinical trial, 156 patients with SAP were randomized into either the placebo (glucose) group or the SM extract (salvianolate injection and Danshen drop pills) group in a 1:1 ratio ([@B10]). Participants were treated with glucose or salvianolate injection (200 mg/250 ml 0.9% saline injection, IV drip, qd) for 10 days during hospitalization, followed by the open-label Danshen drop spill (30 pills/day) in the SM extract group for 60 days after discharge ([@B10]). Using assessment tools, including the Seattle Angina Questionnaire (SAQ), frequency of AP, angina grade, consumption of short-acting nitrates, and so forth, it was demonstrated that SM extract is beneficial for SAP ([@B10]). In addition, previous study reported that five SM-based preparations were effective in the treatment of SAP with clinical improvement rate of 72.4% to 91.6% and electrocardiogram (ECG) improvement rate of 54.5% to 71.6% ([@B139]). The order of five SM-based preparations was as follows: Danhong injection \> salvianolate injection \> STS injection \> Danshen injection of bioactive compounds \> Danshen injection ([@B139]).

In another randomized controlled trial (RCT), 100 UAP patients were randomized into two groups that received STS injection (60 mg/250 ml 0.9% sodium chloride injection, qd, 4 weeks) combined with a loading dose of 300 mg aspirin and a maintenance dose of 100 mg of aspirin plus baseline therapy, or 250 ml 0.9% sodium chloride injection (qd, 4 weeks) combined with the same doses of aspirin and baseline therapy ([@B126]). The severity of AP ameliorated in 94 patients who completed the treatment, with a significant amelioration in total effective rate in the trial groups ([@B126]). STS can significantly reduce the AP attacks in patients with UAP, which may be associated with decreased levels of fibrinogen (FIB) ([@B126]). Moreover, in 17 RCTs involving 1,372 patients, the meta-analysis showed that the combination of STS injection and Western medicine for the treatment of UAP significantly improved the total effective rate and the total effective rate of ECG and reduced the level of CRP, FIB, and whole blood high shear viscosity ([@B102]). In 22 RCTs involving 2,050 patients, the meta-analysis showed that combination of salvianolate injection and Western medicine in the treatment of UAP improved the total effective rate and the total effective rate of ECG, and increased the serum NO lever ([@B138]). Therefore, the combined use of STS injection and salvianolate injection was more effective than Western medicine ([@B138]; [@B102]).

Myocardial Infarction {#s4_2}
---------------------

MI, also known as acute MI (AMI), is the most severe manifestation of CAD, which causes more than 4 million deaths in northern Asia and Europe, and more than 2 to 4 million deaths in the United States ([@B75]; [@B30]; [@B111]). Atherosclerotic plaque rupture is the cause of approximately 70% MI ([@B4]). Patients who survive from AMI may subsequently suffer HF, manifested as fibrotic scar tissue, thinning of the ventricular wall, and reduced systolic function ([@B76]; [@B111]).

Fifty-two patients with non-ST elevation MI (NSTEMI) undergoing PCI were randomized into two groups that received the conventional therapy (n = 26) or the conventional therapy plus SM (n = 26, 1 g each time, three times per day for 1 month after PCI) ([@B140]). Elevated levels of asymmetric dimethylarginine (ADMA) in serum are associated with cardiovascular events and are one of the important biomarkers for predicting adverse events and patient mortality after PCI ([@B63]; [@B22]). The plasma ADMA level in the two groups was significantly decreased at day 30 after PCI with statistical difference, but the reduction in the SM treatment group was more obvious ([@B140]). The improvement of prognosis after the application of SM in patients with PCI may be related to the negative regulation of ADMA by SM ([@B140]). One hundred eight patients with AMI undergoing PCI were randomized into two groups that received the routine treatment (n = 46) or the routine treatment plus intravenous infusion of salvianolate injection (n = 62, 200 mg administered once at 24 h before surgery, once a day after surgery, 1 week) ([@B143]). The changes of oxidative stress indexes, hemodynamic indexes, cardiac function indexes, and related biochemical indicators were analyzed in the two groups at 24 h before surgery and the 8th day after surgery ([@B143]). It was found that salvianolate injection can effectively improve oxidative stress, enhance myocardial perfusion volume, and promote cardiac function recovery in the perioperative period of PCI ([@B143]). In a double-blind RCT, 35 patients with STEMI undergoing PCI were eligible for qi-yin deficiency syndrome, and blood stasis syndromes were randomized into two groups that received Western medicine (n = 18) or Western medicine plus American ginseng and SM preparations (n = 17) for 3 months ([@B86]). At the state of dobutamine stress, the left ventricular ejection fraction (LVEF) in the treatment group was higher than that in the control group, and the symptoms of TCM were improved ([@B86]). Therefore, TCM treatment can improve the clinical symptoms and quality of life of AMI patients undergoing PCI, and is conducive to myocardial microcirculation ([@B86]). A statistical study has shown that the mortality of SM preparation plus conventional care AMI patients is approximately halved compared to conventional care alone (Peto odds ratio, 0.46; 95% confidence interval, 0.28--0.75) ([@B119]).

Hypertension {#s4_3}
------------

Hypertension is a complex disease involving multiple organ systems, a primary modifiable risk factor for heart disease ([@B87]), and one of the most common non-communicable diseases in the world, with an increasing incidence rate in developing countries ([@B34]; [@B3]; [@B73]). Hypertension is often termed the "silent killer" because many hypertensive patients do not know they have the disease before the onset ([@B87]). Uncontrolled hypertension causes many complications including but not limited to HF, heart attacks, kidney failure, aneurysms, strokes, and dementia ([@B87]). The other symptoms include aging ([@B103]), overweight or obesity ([@B93]; [@B106]), dyslipidemia ([@B49]), resting heart rate (RHR) ([@B2]), hyperuricemia ([@B48]), impaired glucose regulation ([@B74]; [@B101]), and estimated glomerular filtration rate (eGFR) ([@B100]); these are considered independent risk factors for the development of hypertension ([@B44]).

In a double-blind, placebo-controlled, randomized, single-center clinical trial, 55 patients with uncontrolled mild to moderate dose for hypertension were randomized into two groups that received Fufang Danshen capsule (formula mixture, 1,000 mg, twice daily, n = 30) or placebo capsules (n = 25) for 12 weeks ([@B131]). The results showed that the Fufang Danshen extract had reduced systolic blood pressure and pulse rate; also it was found that it was well tolerated in patients with hypertension, and no significant difference in adverse effects between the two groups was found ([@B131]).

Pulmonary Heart Disease {#s4_4}
-----------------------

Cor pulmonale \[pulmonary heart disease (PHD)\] is a chronic progressive complicated disease that requires continuous treatment and imposes a huge financial burden on individuals and society ([@B60]). PHD is defined as right ventricular failure secondary to pulmonary hypertension (PH), which is mainly caused by various lung diseases, such as chronic obstructive pulmonary disease (COPD) or pulmonary vascular disease ([@B36]; [@B115]; [@B43]). PH caused by respiratory system diseases and/or chronic hypoxemia is the main pathological mechanism of chronic PHD ([@B95]; [@B91]). Antibiotics, diuretics, oxygen therapy, vasodilators, and anticoagulants are currently used medicines for the treatment of PHD; also, some studies have shown that the safety and effectiveness of TCM combined with conventional treatment is useful in the treatment of these diseases ([@B91]).

The results of many clinical trials have indicated that SM and compound Danshen injection may be alternatives to PHD ([@B60]). A systematic review of the efficacy and safety of SM and compound Danshen injection in PHD patients involved 2,715 patients identified in 35 RCTs ([@B60]). Meta-analysis used I^2^ test for heterogeneity, and randomized or fixed models were selected based on the heterogeneity of the included studies ([@B60]). SM and compound Danshen injection have reached favorable conclusions in reducing blood viscosity, plasma viscosity, hematocrit, and mean pulmonary artery pressure (mPAP) by improving blood partial pressure of oxygen (PaO~2~) ([@B60]). In a study enrolled in five hospitalized inpatients, these patients were suffering from various types of serious PH and did not receive the sufficient benefits from sildenafil treatment for at least 3 months ([@B110]). After 8 weeks of STS infusion, the patient's exercise capacity improved, and the Borg dyspnea score was significantly reduced, demonstrating that STS alone or in combination with sildenafil for PH treatment showed significant effect ([@B110]). In an RCT, 20 children with congenital heart defects and PH were randomly assigned to two groups that received placebo (n = 10) or SM (200 mg/kg, IV, after anesthesia induction, and at the time of rewarming, n = 10) before cardiac surgery ([@B121]). The outcome has indicated that SM helps to reduce the ET-1 response and is associated with increased hemodynamic stability after surgery, thereby exerting potent antioxidant therapeutic effect ([@B121]). Moreover, another clinical trial demonstrated that SM can significantly attenuate lipid peroxide reaction, regulate the imbalance of three antioxidant enzymes \[RBC superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase (CAT)\], and enhance the body's defense ability against free radical-induced lipid peroxidation damage ([@B142]).

Hyperlipidemia {#s4_5}
--------------

Hyperlipidemia is a common disease caused by abnormal blood lipid metabolism, which is considered to be a highly independent risk factor for atherosclerotic cardiovascular and cerebrovascular diseases, such as CHD and stroke ([@B90]). Hyperlipidemia is the result of complex interactions between genetic and environmental factors, which can be treated by altering the diet and drugs that regulate lipid metabolism through many mechanisms ([@B19]). More than 50 TCM formulas have been used to treat hyperlipidemia, of which SM is thought to be beneficial to patients primarily by improving cardiovascular function ([@B122]). In an RCT, 81 hyperlipidemia patients with phlegm and blood stasis syndrome were randomized into two groups that received CDDP (n = 40) or simvastatin (n = 41) for 3 months ([@B145]). The results of this study have shown that CDDP has the effective action for lowering the blood lipid levels without impairing liver function, and its protective liver function may be related to its role in improving antioxidant and reducing inflammation ([@B145]).

Conclusion and Future Perspective {#s5}
=================================

TsIIA, the main bioactive component of SM, has many physiological functions, including antioxidative, anti-inflammatory, endothelial protective, myocardial protective, anticoagulation, vasodilation, anti-AS, and reduction of VSMC proliferation and migration. However, TsIIA has poor oral absorption and low bioavailability. It can be used as a water-soluble derivative of STS, for preparation of new dosage forms, such as microemulsion for injection, microspheres, solid dispersions, liposomes, and nanoparticles. Salvianolate, a major hydrophilic compound of Danshen, has a variety of cardiovascular protective effects, including antioxidative, anti-inflammatory, endothelial protection, myocardial protection, vasodilation, and anti-AS. Both TsIIA and salvianolate have cardioprotective effects with significant differences in their action of mechanism and effect ([@B112]). For example, tanshinone acts early after ischemic injury, mainly by inhibiting intracellular calcium and cell adhesion pathways, whereas salvianolic acid acts primarily by down-regulating apoptosis ([@B112]). Some problems remain to be resolved and should be studied by targeting water-soluble and lipid-soluble components of SM having more or less effects on other CVDs, and whether their effects are consistent at different pathological stages and intervention mechanism. By reviewing clinical studies, it has been found that SM preparations have a good application in the treatment of CHD, hypertension, hyperlipidemia, PHD, and other diseases. However, there is a slight difference in Danshen preparation as STS injection has curative effect in the treatment of CHD, AP, PHD, and other diseases; The adjuvant medicine for the treatment of CVDs, compound Danshen injection can improve the symptoms of patients especially when combined with Western medicine; salvianolate injection has the function of promoting blood circulation and collaterals, and is often used for the treatment of cardiovascular and cerebrovascular diseases, such as AP and MI; CDDP is one of the typical representatives of compound Danshen preparation, which can be used to treat hypertension, hyperlipidemia, and other diseases. Therefore, SM plays an important role in the treatment of CVDs and has a better understanding of the pharmacological mechanism of the monomers of its active ingredients. The existing clinical research results can only be used as a partial reference. More rigorous scientific clinical research data are needed to support for the selection of Danshen preparations with effective regime in certain CVDs.

TCM contains a variety of active ingredients, which act on multiple targets in a complex disease network. Medicines exert synergistic effects on each target to intervene in the occurrence and development of the disease, and finally achieve therapeutic effects ([@B30]). At the same time, it is unclear which ingredients have produced practical effects, which makes the monomer of Chinese herbal medicines a hot spot of concern. Both basic research and clinical observation have made progress, which shows that TCM has huge advantages and prospects, but there are still deficiencies, such as the lack of uniform application standards. The composition and target of SM are more complicated, but with less adverse reactions. It is often used in combination with other medicines, which poses a hidden danger for the adverse reactions with combinations. TCMs may be used as a supplement and alternative to primary and secondary prevention of CVDs, but further rigorous design of RCTs is needed to assess the impact of TCMs on total mortality and major adverse cardiovascular events in patients with CVDs ([@B37]). Multicenter, large samples, and RCTs are also needed to evaluate the safety and efficacy of Danshen preparations for CVDs.
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